Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31474676 | 0.90 | ALOX15 (0.74) | CYP1A2LMNAAGTR1KDM4EALOX15 | |
| SCHEMBL26326254 | 0.90 | CYP1A2 (0.81) | CYP1A2LMNAAGTR1KDM4EALOX15 | |
| SCHEMBL15677621 | 0.87 | ALOX15 (0.70) | CYP1A2LMNAAGTR1KDM4EALOX15 | |
| Guaifenesin SCHEMBL31161209 | 0.85 | CYP1A2 (1.00) | CYP1A2LMNAAGTR1KDM4EALOX15 | |
| Guaifenesin SCHEMBL4321 | 0.85 | CYP1A2 (1.00) | CYP1A2LMNAAGTR1KDM4EALOX15 | |
| Guaifenesin SCHEMBL4322 | 0.85 | CYP1A2 (1.00) | CYP1A2LMNAAGTR1KDM4EALOX15 | |
| Guaifenesin SCHEMBL29759010 | 0.85 | CYP1A2 (1.00) | CYP1A2LMNAAGTR1KDM4EALOX15 | |
| Guaifenesin SCHEMBL160234 | 0.85 | CYP1A2 (1.00) | CYP1A2LMNAAGTR1KDM4EALOX15 | |
| SCHEMBL11711802 | 0.84 | ALOX15 (0.66) | CYP1A2LMNAAGTR1KDM4EALOX15 | |
| Guaifenesin SCHEMBL2459821 | 0.84 | CYP1A2 (0.96) | CYP1A2LMNAAGTR1KDM4EALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3003285-B1 | SOLID PHARMACEUTICAL DOSAGE FORM FOR RELEASE OF AT LEAST TWO ACTIVE PHARMACEUTICAL INGREDIENTS IN THE ORAL CAVITY | MCNEIL AB (SE) | 2022-02-16 | — | — | EP | claimed |
| EP-3003285-A1 | SOLID PHARMACEUTICAL DOSAGE FORM FOR RELEASE OF AT LEAST ONE ACTIVE PHARMACEUTICAL INGREDIENT IN THE ORAL CAVITY | McNeil AB (SE) | 2016-04-13 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2014196916-A1 | SOLID PHARMACEUTICAL DOSAGE FORM FOR RELEASE OF AT LEAST ONE ACTIVE PHARMACEUTICAL INGREDIENT IN THE ORAL CAVITY | MCNEIL AB (SE) | 2014-12-11 | — | — | WO | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| EP-3003285-B1 | SOLID PHARMACEUTICAL DOSAGE FORM FOR RELEASE OF AT LEAST TWO ACTIVE PHARMACEUTICAL INGREDIENTS IN THE ORAL CAVITY | MCNEIL AB (SE) | 2022-02-16 | — | — | EP | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-10463611-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| US-5273993-A | Antiarthritic agents; osteoporosis | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-12-28 | — | — | US | disclosed |
| US-5194446-A | Antiarthritic agents | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-03-16 | — | — | US | disclosed |
| US-5192785-A | Sulfamates as antiglaucoma agents | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-03-09 | — | — | US | disclosed |
| US-5025031-A | Aryl and aryloxyalkyl sulfamate esters useful as anticonvulsants | A. H. ROBINS CO., INC. (US) | 1991-06-18 | — | — | US | disclosed |
| EP-0403185-A2 | Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals | A.H. ROBINS COMPANY, INCORPORATED (US) | 1990-12-19 | — | — | EP | disclosed |